Cash ReservesOncternal ended the year with roughly $34.3M in cash, cash equivalents, and marketable securities, providing an operational runway into 2025, which boosts financial stability.
Clinical TrialsEnrollment has been completed and dosing initiated for the fifth dose cohort of ONCT-534, with no dose-limiting toxicities observed so far, indicating strong potential for this dual-action androgen receptor inhibitor.
Financial PerformanceThe reported net loss per share was narrower than previously estimated, driven by lower-than-expected operating expenses, signaling better financial management.